Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death

PLoS One. 2012;7(9):e45213. doi: 10.1371/journal.pone.0045213. Epub 2012 Sep 19.

Abstract

It has been proposed that Mycobacterium tuberculosis virulent strains inhibit apoptosis and trigger cell death by necrosis of host macrophages to evade innate immunity, while non-virulent strains induce typical apoptosis activating a protective host response. As part of the characterization of a novel tuberculosis vaccine candidate, the M. tuberculosis phoP mutant SO2, we sought to evaluate its potential to induce host cell death. The parental M. tuberculosis MT103 strain and the current vaccine against tuberculosis Bacillus Calmette-Guérin (BCG) were used as comparators in mouse models in vitro and in vivo. Our data reveal that attenuated SO2 was unable to induce apoptotic events neither in mouse macrophages in vitro nor during lung infection in vivo. In contrast, virulent MT103 triggers typical apoptotic events with phosphatidylserine exposure, caspase-3 activation and nuclear condensation and fragmentation. BCG strain behaved like SO2 and did not induce apoptosis. A clonogenic survival assay confirmed that viability of BCG- or SO2-infected macrophages was unaffected. Our results discard apoptosis as the protective mechanism induced by SO2 vaccine and provide evidence for positive correlation between classical apoptosis induction and virulent strains, suggesting apoptosis as a possible virulence determinant during M. tuberculosis infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / immunology
  • BCG Vaccine / administration & dosage
  • BCG Vaccine / immunology*
  • Caspase 3 / metabolism
  • Cell Nucleus / microbiology
  • Cell Nucleus / pathology
  • Cell Survival / immunology
  • Cells, Cultured
  • Host-Pathogen Interactions
  • Humans
  • Macrophages / immunology
  • Macrophages / microbiology*
  • Macrophages / pathology
  • Mice
  • Mycobacterium tuberculosis / immunology
  • Mycobacterium tuberculosis / pathogenicity*
  • Phosphatidylserines / chemistry
  • Tuberculosis Vaccines / administration & dosage
  • Tuberculosis Vaccines / immunology*
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / microbiology
  • Tuberculosis, Pulmonary / pathology
  • Tuberculosis, Pulmonary / prevention & control*
  • Vaccination*
  • Vaccines, Attenuated
  • Virulence

Substances

  • BCG Vaccine
  • Phosphatidylserines
  • Tuberculosis Vaccines
  • Vaccines, Attenuated
  • Caspase 3

Grants and funding

This work was supported by grant SAF2007-65144 (AA), BIO2008-01561 (CM), BIO2011-23555 (CM), SAF2008-02139 (JP), and SAF2011-25390 (JP) from the Spanish Ministery of Science and Innovation and grant FP7 European NEWTBVAC 241745. Julian Pardo was supported by Aragón I+D Foundation (ARAID), Adriana Aporta was supported by a fellowship from Cuenca Villoro Foundation and Ainhoa Arbues by BES-2006-11950. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.